_Market_1.jpg)
The Peptide–Drug Conjugates (PDCs) Market Size is valued at USD 3.80 Bn in 2024 and is predicted to reach USD 21.10 Bn by the year 2034 at a 18.8 % CAGR during the forecast period for 2025-2034.
The emergence of Peptide–Drug Conjugates (PDCs) therapy for patients suffering from different cancers is believed to create several clinical opportunities during the forecast period. Peptide drug conjugates comprise three vital components: a homing peptide, a linker, and a cytotoxic payload that targets the tumour cell to release the cytotoxin. PDC targets tumour cells with a peptide chain of about ten amino acids, and its molecular weight is smaller than Antibody Drug Conjugates (ADCs), which can be rapidly enriched to tumour sites, while drug molecules in blood can be cleared quickly with a short half-life, helping to reduce toxic side effects caused by off-targeting. Due to the increasef popularity of ADCs, the pharmaceutical industry has been pushed to investigate additional drug conjugates, resulting in the development of a vast array of innovative Conjugated Drugs.
Therapeutic drugs are anticipated to be driven by the rising partnerships, mergers, and acquisitions of market players. The increasing number of pharmaceutical drug innovations is expected to fuel the growth of peptide–drug conjugates (PDCs) market in the near future. Also, in the coming days, there will be rapid approval of peptide drug conjugates in treating cancers due to the robust clinical pipeline of drugs. Major driving factors of peptide–drug conjugates (PDCs) market are the increasing need for therapeutic drugs, high prevalence of cancer diseases, rising number of clinical trials, and increasing investments by key players to develop promising therapies. Furthermore, advanced medical technologies, population growth, and the growing number of health-conscious people enhance the market growth.
However, the high-cost treatments, complex procedures, and lack of strict government laws limit the market growth. In addition, the pipeline product approval process may get responsible for the delayed product launch, and production as a lot of clinical trials are progressive stages. FDA has approved very few pipeline products regarding peptide drug conjugates in the last five years, which will impact the market's forecasting period.
The Peptide Drug conjugate Market is segmented by product type, therapeutic application, product, and type. The Product Type segment comprises Radiopharmaceutical PDCs, Cytotoxic PDCs, Diagnostic PDCs, Emerging PDCs. By Therapeutic Application segment, the market classified into Oncology, Neuroendocrine Tumors, Prostate Cancer, Solid Tumors, Hematologic Cancers, Neurological Disorders, Metabolic Diseases, Infectious Diseases. As per the Type segment, the market is further divided into Therapeutic, Diagnostic. The Product segment includes OctreoScan, Lutathera, Pluvicto, Illuccix, Others. The peptide–drug conjugates (PDCs) market is divided into North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa. North America, followed by Europe, holds the maximum market share due to the high prevalence of cancer, increased research and development expenditure, and fast adaption of advanced technologies. Due to factors such as growing per capita healthcare spending, well-established research facilities for the development of innovative PDCs, preclinical research, and increased research on advanced drug discoveries, the United States has the largest market share in the North American region.
|
Report Attribute |
Specifications |
|
Market size value in 2024 |
USD 3.80 Bn |
|
Revenue forecast in 2034 |
USD 21.10 Bn |
|
Growth rate CAGR |
CAGR of 18.8 % from 2025 to 2034 |
|
Quantitative units |
Representation of revenue in US$ Million and CAGR from 2024 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments covered |
By product type, therapeutic application, product, and type |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; South East Asia |
|
Competitive Landscape |
Novartis AG, AstraZeneca, Bicycle Therapeutics, Cybrexa Therapeutics, Esperance Pharmaceuticals, Oncopeptides AB, Pepgen Corporation, Soricimed Biopharma, Theratechnologies, Pfizer Inc, Validus Pharmaceuticals LLC, Antisense Therapeutics, Midatech Pharma PLC, Ipsen Pharma, Chiasma, Inc., Peptron, Inc., CRINETICS PHARMACEUTICALS, Dauntless Pharmaceuticals, Camurus AB, Teva Pharmaceuticals Inc., Pharmaspur, Aspireo Pharmaceuticals, Ionis Pharmaceuticals Inc, Midatech Pharma Plc, and Other Prominent Players. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Peptide–Drug Conjugates (PDCs) Market Snapshot
Chapter 4. Global Peptide–Drug Conjugates (PDCs) Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Global Peptide–Drug Conjugates (PDCs) Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on PEPTIDE–DRUG CONJUGATES (PDCS) MARKET Industry Trends
Chapter 5. Peptide–Drug Conjugates (PDCs) Market Segmentation 1: By Product Type, Estimates & Trend Analysis
5.1. Market Share By Product Type, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product Type:
5.2.1. Radiopharmaceutical PDCs
5.2.2. Cytotoxic PDCs
5.2.3. Diagnostic PDCs
5.2.4. Emerging PDCs
Chapter 6. Peptide–Drug Conjugates (PDCs) Market Segmentation 2: By Product, Estimates & Trend Analysis
6.1. Market Share By Product, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product:
6.2.1. OctreoScan
6.2.2. Lutathera
6.2.3. Pluvicto
6.2.4. Illuccix
6.2.5. Others
Chapter 7. Peptide–Drug Conjugates (PDCs) Market Segmentation 3: By Therapeutic Application, Estimates & Trend Analysis
7.1. Market Share By Therapeutic Application, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:
7.2.1. Oncology
7.2.2. Neuroendocrine Tumors
7.2.3. Prostate Cancer
7.2.4. Solid Tumors
7.2.5. Hematologic Cancers
7.2.6. Neurological Disorders
7.2.7. Metabolic Diseases
7.2.8. Infectious Diseases
Chapter 8. Peptide–Drug Conjugates (PDCs) Market Segmentation 4: By Type, Estimates & Trend Analysis
8.1. Market Share By Type, 2024 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Vessel Type:
8.2.1. Therapeutic
8.2.2. Diagnostic
Chapter 9. Peptide–Drug Conjugates (PDCs) Market Segmentation 6: Regional Estimates & Trend Analysis
9.1. Global Peptide–Drug Conjugates (PDCs) Market, Regional Snapshot 2024 & 2034
1.1. North America
1.1.1. North America Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
1.1.1.1. United States
1.1.1.2. Canada
1.1.2. North America Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Product Type, 2021-2034
1.1.3. North America Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Product, 2021-2034
1.1.4. North America Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Therapeutic Application, 2021-2034
1.1.5. North America Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Type, 2021-2034
1.2. Europe
1.2.1. Europe Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
1.2.1.1. Finland
1.2.1.2. UK
1.2.1.3. France
1.2.1.4. Germany
1.2.1.5. Netherland
1.2.1.6. Spain
1.2.1.7. Rest of Europe
1.2.2. Europe Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Product Type, 2021-2034
1.2.3. Europe Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Product, 2021-2034
1.2.4. Europe Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Therapeutic Application, 2021-2034
1.2.5. Europe Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Type, 2021-2034
1.3. Asia Pacific
1.3.1. Asia Pacific Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
1.3.1.1. China
1.3.1.2. Japan
1.3.1.3. South Korea
1.3.1.4. Rest of Asia Pacific
1.3.2. Asia Pacific Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Product Type, 2021-2034
1.3.3. Asia Pacific Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Product, 2021-2034
1.3.4. Asia Pacific Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Therapeutic Application, 2021-2034
1.3.5. Asia Pacific Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Type, 2021-2034
1.3.6. Asia Pacific Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts by Cargo Ships, 2021-2034
1.4. Latin America
1.4.1. Latin America Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
1.4.1.1. GCC Countries
1.4.1.2. Israel
1.4.1.3. South Africa
1.4.1.4. Rest of Middle East and Africa
1.4.2. Latin America Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Product Type, 2021-2034
1.4.3. Latin America Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Product, 2021-2034
1.4.4. Latin America Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Therapeutic Application, 2021-2034
1.4.5. Latin America Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Type, 2021-2034
1.5. Middle East & Africa
1.5.1. Middle East & Africa Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
1.5.1.1. GCC Countries
1.5.1.2. Israel
1.5.1.3. South Africa
1.5.1.4. Rest of Middle East and Africa
1.5.2. Middle East & Africa Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Product Type, 2021-2034
1.5.3. Middle East & Africa Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Product, 2021-2034
1.5.4. Middle East & Africa Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Therapeutic Application, 2021-2034
1.5.5. Middle East & Africa Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Type, 2021-2034
Chapter 2. Competitive Landscape
2.1. Major Mergers and Acquisitions/Strategic Alliances
2.2. Company Profiles
2.2.1. Novartis AG
2.2.1.1. Business Overview
2.2.1.2. Key Product/Service
2.2.1.3. Financial Performance
2.2.1.4. Geographical Presence
2.2.1.5. Recent Developments with Business Strategy
2.2.2. AstraZeneca
2.2.3. Bicycle Therapeutics
2.2.4. Cybrexa Therapeutics
2.2.5. Esperance Pharmaceuticals
2.2.6. Oncopeptides AB
2.2.7. Pepgen Corporation
2.2.8. Soricimed Biopharma
2.2.9. Theratechnologies
2.2.10. Pfizer Inc
2.2.11. Validus Pharmaceuticals LLC
2.2.12. Antisense Therapeutics
2.2.13. Midatech Pharma PLC
2.2.14. Ipsen Pharma
2.2.15. Chiasma, Inc.
2.2.16. Peptron, Inc.
2.2.17. CRINETICS PHARMACEUTICALS
2.2.18. Dauntless Pharmaceuticals
2.2.19. Camurus AB
2.2.20. Teva Pharmaceuticals Inc.
2.2.21. Pharmaspur
2.2.22. Aspireo Pharmaceuticals
2.2.23. Ionis Pharmaceuticals Inc
2.2.24. Midatech Pharma Plc
2.2.25. Other Prominent Players
Global Peptide–drug conjugates (PDCs) Market, by Product Type,
Global Peptide–drug conjugates (PDCs) Market, by Therapeutic Application,
Global Peptide–drug conjugates (PDCs) Market, by Product,
Global Peptide–drug conjugates (PDCs) Market, by Type,
Global Peptide–drug conjugates (PDCs) Market, by Region,
North America Peptide–drug conjugates (PDCs) Market, by Country,
Europe Peptide–drug conjugates (PDCs) Market, by Country,
Asia Pacific Peptide–drug conjugates (PDCs) Market, by Country,
Latin America Peptide–drug conjugates (PDCs) Market, by Country,
Middle East & Africa Peptide–drug conjugates (PDCs) Market, by Country,
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
